Tenderwize
Retour à la recherche

Non-exclusive drug rebate agreement for Naloxegol

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naloxegol (ATC-Code nach WHO: A06AH03)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed volume or minimum purchase; actual revenue may be negligible.

The buyer may terminate the Open-House early if exclusive agreements are concluded, leading to termination of existing...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive pharmaceutical rebate agreement for Naloxegol
  • Drug supply to AOK PLUS insured members in Saxony and Thuringia
Afficher le résumé complet

This tender from AOK PLUS is a non-exclusive pharmaceutical rebate agreement for the active substance Naloxegol (ATC A06AH03) under § 130a Abs. 8 SGB V, using an Open-House model. It is not a traditional public procurement; it is published for transparency. Any qualified pharmaceutical company can join by accepting the terms. No minimum volumes, no exclusivity, and no individual negotiations. The agreement ends 31 July 2027. The estimated value is not disclosed, and the volume is unknown. This is a framework-like arrangement with rolling submission deadlines.

Risques

No guaranteed volume or minimum purchase; actual revenue may be negligible.

The buyer may terminate the Open-House early if exclusive agreements are concluded, leading to termination of existing...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG, with seat in Germany, EU, or EEA

Eligibility

  • Must submit completed declaration on exclusion grounds (§§123,124 GWB)

Administrative

  • Must submit declaration on Russia sanctions compliance

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable; participation is open to all qualified parties.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug rebate agreement for Naloxegol

Conclusion of non-exclusive rebate agreements for Naloxegol within an Open-House model. The buyer reserves the right to terminate early if exclusive agreements are concluded.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable; participation is open to all qualified parties.

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
29 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
350276-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30